Surrozen, Inc./DE (SRZN)
About Surrozen, Inc./DE
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $3.5M
- Net income
- -$242.0M
- Total assets
- $98.7M
- Market cap
- $229.1M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $229.1M
- Shares outstanding
- 9.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 12, 2021
Surrozen, Inc./DE (SRZN) Stock Price
- Reported a net loss of $242.0M in FY2025.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Surrozen, Inc./DE.
Write a review
News about Surrozen, Inc./DE
News & sentiment via Polygon.io
Surrozen, Inc./DE: frequently asked questions
Is Surrozen, Inc./DE an American company?
Surrozen, Inc./DE is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Surrozen, Inc./DE headquartered?
Surrozen, Inc./DE is headquartered in South San Francisco, California, United States.
Is Surrozen, Inc./DE publicly traded?
Yes — Surrozen, Inc./DE is a publicly traded company. Its stock trades under the ticker symbol SRZN on the NASDAQ.
What does Surrozen, Inc./DE do?
Surrozen, Inc./DE is an American Pharmaceuticals company in the Health & Beauty sector.
